Validating an instrument
Hence, the clinical question of who should continue taking anticoagulants indefinitely and who can safely discontinue them after short term treatment for unprovoked VTE remains a high research priority.910 To answer this important question, the long term risks and burdens of recurrent VTE must be balanced against the long term risks and burdens of oral anticoagulant treatment, especially major bleeding.
The International Society on Thrombosis and Haemostasis suggests that it is safe to discontinue anticoagulants if the risk of recurrent VTE is less than 5% at one year after discontinuing treatment.12 To date, no clinical decision rules 131415 designed to achieve these standards have been prospectively validated.
Unit readiness, movementdates, passengers, and cargo details should be confirmed with theunit before validation occurs.
See also independent review; time-phased force and deployment data; verification.
We previously derived a clinical decision rule to identify patients at low risk of recurrent VTE who could discontinue anticoagulants.15 The clinical decision rule, HERDOO2, identifies women with one or fewer of the four following criteria as being at low risk of recurrent VTE: Hyperpigmentation, Edema, or Redness in either leg; D-dimer level ≥250 μg/L during treatment with anticoagulants; Obesity with body mass index ≥30; and Older age, ≥65 years (fig 1).15 No subgroup of men could be identified as low risk for recurrent VTE.
Participants Of 3155 consecutive eligible participants with a first unprovoked venous thromboembolism (VTE, proximal leg deep vein thrombosis or pulmonary embolism) who completed 5-12 months of short term anticoagulant treatment, 370 declined to participate, leaving 2785 enrolled participants. Interventions Women with none or one of the HERDOO2 criteria were classified as at low risk of recurrent VTE and discontinued anticoagulants (intervention arm), whereas anticoagulant management for high risk women (≥2 HERDOO2 criteria) and men was left to the discretion of the clinicians and patients (observation arm).The page below includes all of the violin facts we have come across.We are now beginning the process of validating them one by one.Check back as we update this page with what we find! A process associated with the collection and production of intelligence that confirms that an intelligence collection or production requirement is sufficiently important to justify the dedication of intelligence resources, does not duplicate an existing requirement, and has not been previously satisfied.2.